BLUE bluebird bio Inc.: Enterprise Value-to-Revenue Multiple

bluebirdbio.com (BLUE) - corporate logo

bluebird bio, Inc. (BLUE) specializes in gene therapy for rare pathologies, where cash flows remain unstable due to the complexity of drug approvals. High R&D costs are offset by patent rights, which ensure significant profit per dose. The EV/Sales trajectory, where the value represents the most recent figure, is supplemented by compliance with environmental standards regarding chemical disposal.

bluebird bio, Inc. - BLUE EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

bluebird bio, Inc - analytical breakdowns and key metrics (BLUE)

- market price and analyst price targets:
- cash and cash flow indicators:
Fundamental valuation:BLUE (bluebird bio, Inc.)
Finished products of Bluebird Bio

The investment attractiveness of bluebird bio, Inc. (BLUE) depends on the market's ability to value its potential amid geopolitical fragmentation that restricts international research. The EV/Sales metric provided by GURU.Markets determines the enterprise value relative to revenue, while the trend of company value to revenue reflects the extent to which capitalization outpaces actual sales under the pressure of logistical sanctions.

Competitor analysis for bluebird bio, Inc.

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple